Brand names: Linezolid
Oxazolidinone Antibacterial
Route: Oral
Contraindications
4 CONTRAINDICATIONS · Known hypersensitivity to linezolid or any of the other product components. (4.1) • Patients taking any monoamine oxidase inhibitors (MAOI) or within two weeks of taking an MAOI. (4.2) 4.1 Hypersensitivity Linezolid tablets are contraindicated for use in patients who have known hypersensitivity to linezolid or any of the other product components . 4.2 Monoamine Oxidase Inhibitors Linezolid should not be used in patients taking any medicinal product which inhibits monoamine oxidases A or B (e.g., phenelzine, isocarboxazid) or within two weeks of taking any such medicinal product.
Pregnancy & Breastfeeding
8.1 Pregnancy Risk Summary Available data from published and postmarketing case reports with linezolid use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. When administered during organogenesis, linezolid did not cause malformations in mice, rats, or rabbits at maternal exposure levels approximately 6.5 times (mice), equivalent to (rats), or 0.06 times (rabbits) the clinical therapeutic exposure, based on AUCs. However, embryo-fetal lethality was observed in mice at 6.5 times the estimated human exposure. When female rats were dosed during organogenesis through lactation, postnatal survival of pups was decreased at doses approximately equivalent to the estimated human exposure based on AUCs ( see Data ) . The background risk of major birth defects and miscarriage for the indicated populations is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Data Animal Data In mice, embryo-fetal toxicities were observed only at doses that caused maternal toxicity (clinical signs and reduced body weight gain). An oral dose of 450 mg/kg/day given from Gestation Day (GD) 6 to 16 (6.5 times the estimated human exposure based on AUCs) correlated with increased postimplantational embryo death, including total litter loss, decreased fetal body weights, and an increased incidence of costal cartilage fusion. Neither maternal nor embryo-fetal toxicities were observed at doses up to 150 mg/kg/day. Fetal malformations were not observed. In rats, fetal toxicity was observed at 15 and 50 mg/kg/day administered orally from GD 6-17 (exposures 0.22 times to approximately equivalent to the estimated human exposure, respectively, based on AUCs). The effects consisted of decreased fetal bo
49 interactions on record
Concomitant use contraindicated. Serious, sometimes fatal reactions including hyperthermia, rigidity, myoclonus, and autonomic instability reported with MAOIs like linezolid.
Source: NLP:atomoxetine hydrochloride
Reversible MAOI; starting buspirone is contraindicated due to increased risk of serotonin syndrome.
Source: NLP:buspirone hydrochloride
Concomitant use increases risk of serotonin syndrome. Citalopram is contraindicated in patients taking linezolid.
Source: NLP:citalopram
Concomitant use increases risk of serotonin syndrome. Citalopram is contraindicated in patients taking linezolid.
Source: NLP:citalopram hydrobromide
Concomitant use increases risk of serotonin syndrome. Contraindicated due to MAOI-like activity.
Source: NLP:desvenlafaxine
Concomitant use increases risk of serotonin syndrome. Contraindicated in patients being treated with linezolid.
Source: NLP:desvenlafaxine er
Concomitant use is contraindicated due to increased risk of serotonin syndrome.
Source: NLP:desvenlafaxine succinate
Concomitant use can cause hypertensive crisis with potential outcomes including death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure.
Source: NLP:dexmethylphenidate hydrochloride
MAOI that potentiates amphetamine effects; concomitant use can cause hypertensive crisis with potentially fatal outcomes including stroke, MI, aortic dissection.
Source: NLP:dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate
Linezolid is an MAOI. Concomitant use with doxepin hydrochloride increases risk of serotonin syndrome. Use within 14 days of discontinuation is contraindicated.
Source: NLP:doxepin hydrochloride
Concomitant use should be avoided due to potential for increased blood pressure.
Source: NLP:droxidopa
MAOI with potential to increase serotonin syndrome risk. Escitalopram is contraindicated in patients taking linezolid.
Source: NLP:escitalopram
Concomitant use increases risk of serotonin syndrome. Escitalopram oxalate is contraindicated in patients taking linezolid.
Source: NLP:escitalopram oxalate
Concomitant use increases risk of serotonin syndrome. GEPIRONE is contraindicated in patients taking linezolid or within 14 days of stopping.
Source: NLP:gepirone
Not recommended for patients taking MAOIs or within 14 days of stopping. May manifest as serotonin syndrome or opioid toxicity.
Source: NLP:hydromorphone hydrochloride
MAOI-like antibiotic that increases risk of serotonin syndrome when used with levomilnacipran. Contraindicated use.
Source: NLP:levomilnacipran hydrochloride
Concomitant use can cause hypertensive crisis with potential outcomes including death, stroke, myocardial infarction, and other serious complications.
Source: NLP:methylphenidate hydrochloride
Concomitant use can cause hypertensive crisis with potential outcomes including death, stroke, myocardial infarction, aortic dissection, and renal failure.
Source: NLP:methylphenidate hydrochloride extended release
Avoid use with midodrine.
Source: NLP:midodrine hydrochloride
Do not initiate SAVELLA in patients being treated with linezolid. Discontinue SAVELLA before initiating linezolid treatment.
Source: NLP:milnacipran hydrochloride
Concomitant use increases risk of serotonin syndrome. Mirtazapine is contraindicated in patients taking this MAOI.
Source: NLP:mirtazapine
Linezolid is a reversible, nonselective inhibitor of monoamine oxidase and is contraindicated with MAOIs due to potential serious interactions.
Source: NLP:linezolid
MAOI activity may cause serotonin syndrome or opioid toxicity; do not use morphine in patients taking linezolid or within 14 days of stopping.
Source: NLP:morphine sulfate
Concomitant use increases risk of serotonin syndrome. Paroxetine is contraindicated in patients taking linezolid.
Source: NLP:paroxetine
Concomitant use of SSRIs including paroxetine and MAOIs increases the risk of serotonin syndrome.
Source: NLP:paroxetine hydrochloride
Concomitant use is contraindicated as linezolid is an MAOI with potential for serotonin syndrome.
Source: NLP:paroxetine hydrochloride hemihydrate
Potent MAO inhibitor with reversible nonselective MAO inhibition activity; co-administration increases risk of nonselective MAO inhibition leading to hypertensive crisis.
Source: NLP:safinamide mesylate
Concomitant use increases risk of serotonin syndrome. Sertraline is contraindicated in patients taking MAOIs including linezolid.
Source: NLP:sertraline
Concomitant use of MAOI linezolid with sertraline hydrochloride increases risk of serotonin syndrome.
Source: NLP:sertraline hydrochloride
MAOI activity may cause serotonin syndrome or opioid toxicity. Do not use or within 14 days of stopping.
Source: NLP:tapentadol hydrochloride
Contraindicated; emergency use only with close monitoring and immediate discontinuation of tranylcypromine if necessary.
Source: NLP:tranylcypromine
Contraindicated agent. If emergency treatment necessary, discontinue tranylcypromine immediately and monitor closely for adverse reactions.
Source: NLP:tranylcypromine sulfate
Concomitant use increases risk of serotonin syndrome. Trazodone is contraindicated with linezolid and intravenous methylene blue.
Source: NLP:trazodone hydrochloride
Concomitant use with linezolid (an MAOI) increases the risk of serotonin syndrome and is contraindicated.
Source: NLP:venlafaxine
MAOI with properties that increase risk of serotonin syndrome when used with venlafaxine. Contraindicated.
Source: NLP:venlafaxine hcl er
Concomitant use with linezolid (MAOI) increases risk of serotonin syndrome. Contraindicated in patients taking linezolid.
Source: NLP:venlafaxine hydrochloride
MAOI that increases risk of serotonin syndrome when combined with vilazodone hydrochloride.
Source: NLP:vilazodone hydrochloride
Concomitant use increases risk of serotonin syndrome. Contraindicated with linezolid or within 21 days of stopping vortioxetine.
Source: NLP:vortioxetine
Linezolid has potential for interaction with adrenergic agents; monitoring and caution required.
Source: NLP:linezolid
MAOI-like interaction with opioids may result in serotonin syndrome or opioid toxicity including respiratory depression and coma.
Source: NLP:atropa belladonna and opium
Inhibition of MAO prolongs and potentiates dopamine effects, potentially resulting in severe hypertension and cardiac arrhythmia.
Source: NLP:dopamine hydrochloride
Concomitant use has resulted in serotonin syndrome.
Source: NLP:levorphanol tartrate
Concomitant use may result in serotonin syndrome. Carefully observe patient during treatment initiation and dosage modification; discontinue metaxalone if serotonin syndrome occurs.
Source: NLP:metaxalone
Concomitant use may result in serotonin syndrome with serious CNS reactions, potentially fatal.
Source: NLP:methylene blue
MAOI-like interaction may manifest as serotonin syndrome.
Source: NLP:nalbuphine hydrochloride
Co-administration can cause severe, prolonged hypertension. Monitor for hypertension if norepinephrine bitartrate cannot be avoided.
Source: NLP:norepinephrine bitartrate
MAOI that can manifest as serotonin syndrome or opioid toxicity including respiratory depression and coma.
Source: NLP:oxymorphone hydrochloride
Concomitant use has resulted in serotonin syndrome. Carefully observe patient during treatment initiation and dose adjustment.
Source: NLP:pentazocine and naloxone
MAOI activity may result in serotonin syndrome or opioid toxicity.
Source: NLP:remifentanil hydrochloride